

25 Jan 2017 | Opinion

In Vivo's 2016 Deals Of The Year: The Winners Are...

by Nancy Dvorin

We nominated 15 deals in three categories. You picked the winners. (Free article.)

Top Alliance: AstraZeneca's Asset Drop

- 38% of you picked [AstraZeneca PLC](#)'s year-long purge of non-core assets, which climaxed in October with five out-licensing deals cumulatively worth more than \$1 billion. [Casebia Therapeutics](#), [Bayer AG](#)'s JV with [CRISPR Therapeutics AG](#), was runner-up with 26% of the vote.

Top Financing: It's A Tie!

- 40% of you voted for the \$474 million equity financing that mRNA drug developer [Moderna Therapeutics LLC](#) closed in September. And 40% voted for [Samsung BioLogics](#)' \$2 billion IPO –a big validation for biologics development in South Korea and also a demonstration of the importance of diversification for parent Samsung.

Top M&A: QuintilesIMS: Big Merger In Big Data

- 31% of you chose Quintiles' \$9 billion merger with IMS Health. QuintilesIMS will have a market cap close to \$18 billion, not to mention a huge head start in finding real-world evidence solutions for clients. [Pfizer Inc.](#)'s \$14 billion buy of [Medivation Inc.](#) was a close second, with 29% of the vote.